✦ LIBER ✦

Oral fumaric acid esters for the treatment of active multiple sclerosis: an open-label, baseline-controlled pilot study

✍ Scribed by S. Schimrigk; N. Brune; K. Hellwig; C. Lukas; B. Bellenberg; M. Rieks; V. Hoffmann; D. Pöhlau; H. Przuntek

Book ID: 111064661
Publisher: John Wiley and Sons
Year: 2006
Tongue: English
Weight: 164 KB
Volume: 13
Category: Article
ISSN: 1351-5101
DOI: 10.1111/j.1468-1331.2006.01292.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Oral fumaric acid esters for the treatme

Oral fumaric acid esters for the treatment of active multiple sclerosis: an open-label, baseline-controlled pilot study

✍ S. Schimrigk; N. Brune; K. Hellwig; C. Lukas; B. Bellenberg; M. Rieks; V. Hoffma 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 164 KB

An exploratory, prospective, open‐label study of fumaric acid esters (FAE, Fumaderm®) was conducted in patients with relapsing–remitting multiple sclerosis (RRMS). The study consisted of the following four phases: 6‐week baseline, 18‐week treatment (target dose of 720 mg/day), 4‐week washout, and a

Autologous mesenchymal stem cells for th

Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study

✍ Peter Connick; Madhan Kolappan; Charles Crawley; Daniel J Webber; Rickie Patani; 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 174 KB

An Open-Label Pilot Study Evaluating by

An Open-Label Pilot Study Evaluating by Magnetic Resonance Imaging the Potential for a Disease-Modifying Effect of Celecoxib Compared to a Modelized Historical Control Cohort in the Treatment of Knee Osteoarthritis

✍ Jean-Pierre Raynauld; Johanne Martel-Pelletier; André Beaulieu; Louis Bessette; 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 239 KB